All Stories

  1. Recent advances in understanding and preventing oesophageal cancer
  2. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
  3. Development of Quality Indicators for Endoscopic Eradication Therapies in Barrett’s Esophagus: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
  4. Development of quality indicators for endoscopic eradication therapies in Barrett’s esophagus: the TREAT-BE (Treatment with Resection and Endoscopic Ablation Techniques for Barrett’s Esophagus) Consortium
  5. Genome-wide association studies in oesophageal adenocarcinoma and Barrett's oesophagus: a large-scale meta-analysis
  6. Response to Feuerstein J et al. “Systematic Analysis and Critical Appraisal of the Quality of the Scientific Evidence and Conflicts of Interest in Practice Guidelines (2005–2013) for Barrett’s Esophagus”. doi:10.1007/s10620-016-4222-2
  7. Germline variation in inflammation-related pathways and risk of Barrett's oesophagus and oesophageal adenocarcinoma
  8. Polymorphism in a lincRNA Associates with a Doubled Risk of Pneumococcal Bacteremia in Kenyan Children
  9. A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies
  10. The genetic associations of acute anterior uveitis and their overlap with the genetics of ankylosing spondylitis
  11. Management of Barrett esophagus: a practical guide for clinicians based on the BADCAT and BoB CAT recommendations
  12. Addendum: BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia
  13. BOB CAT: a Large-Scale Review and Delphi Consensus for Management of Barrett’s Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia
  14. Barrett's Oesophagus Surveillance versus endoscopy at need Study (BOSS): protocol and analysis plan for a multicentre randomized controlled trial
  15. Polymorphisms Near TBX5 and GDF7 Are Associated With Increased Risk for Barrett’s Esophagus
  16. Estimates of benefits and harms of prophylactic use of aspirin in the general population
  17. Trefoil Factor Expression in a Human Model of the Early Stages of Barrett’s Esophagus
  18. Faculty Opinions recommendation of Clinical outcome in patients treated with endoscopic submucosal dissection for superficial Barrett's neoplasia.
  19. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins
  20. Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process
  21. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial
  22. Variability in Working Memory Performance Explained by Epistasis vs Polygenic Scores in theZNF804APathway
  23. Barrett's origins from gastric mucosa
  24. The field effect in Barrett’s esophagus: can we use it for screening and surveillance?
  25. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus
  26. Genome-wide association analysis identifies 13 new risk loci for schizophrenia
  27. Genome-wide association study of intraocular pressure identifies the GLCCI1/ICA1 region as a glaucoma susceptibility locus
  28. A “Candidate-Interactome” Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis
  29. Identification of Lineage-Uncommitted, Long-Lived, Label-Retaining Cells in Healthy Human Esophagus and Stomach, and in Metaplastic Esophagus
  30. Barrett's Esophagus: Evolutionary Insights From Genomics
  31. Genome-wide meta-analyses of multiancestry cohorts identify multiple new susceptibility loci for refractive error and myopia
  32. Tipping the Balance: Benefits and Risks of Aspirin in Chemoprevention of Colorectal Cancer
  33. Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus
  34. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity
  35. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer
  36. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
  37. Genome-Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at the Major Histocompatibility Complex Locus in Schizophrenia
  38. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus
  39. Editorial: Genetics of Barrettʼs: The Bigger, the Better
  40. Conditional analysis identifies three novel major histocompatibility complex loci associated with psoriasis
  41. Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease
  42. Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
  43. Handbook of Gastrointestinal Cancer
  44. Comparing virtual with conventional microscopy for the consensus diagnosis of Barrett’s neoplasia in the AspECT Barrett’s chemoprevention trial pathology audit
  45. Common Genetic Determinants of Intraocular Pressure and Primary Open-Angle Glaucoma
  46. Aspirin and NSAIDs; benefits and harms for the gut
  47. Does aspirin really reduce the risk of colon cancer?
  48. The role of ATM in response to metformin treatment and activation of AMPK
  49. Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke
  50. RHBDF2 Mutations Are Associated with Tylosis, a Familial Esophageal Cancer Syndrome
  51. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor
  52. Endoscopic therapies for the prevention and treatment of early esophageal neoplasia
  53. Aspirin therapy for cancer: it is never too late
  54. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility
  55. Chemoprevention in Barrett’s oesophagus
  56. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis
  57. Guidelines for the management of oesophageal and gastric cancer
  58. Aspirin in the prevention of cancer
  59. The Clonal Origins of Dysplasia From Intestinal Metaplasia in the Human Stomach
  60. Gastroesophageal reflux disease and bulimia nervosa - a review of the literature
  61. Acid Reflux and Oesophageal Cancer
  62. Chemoprevention in Barrett's Esophagus: A Pill a Day?
  63. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes
  64. Does long term aspirin prevent cancer?
  65. Gastroenterology research: where now?
  66. Dissection of the genetics of Parkinson's disease identifies an additional association 5' of SNCA and multiple associated haplotypes at 17q21
  67. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1
  68. Diagnosis and management of Barrett's oesophagus
  69. Authors' response
  70. In vivo analysis of gut function and disease changes in a zebrafish larvae model of inflammatory bowel disease
  71. Cytoplasmic β-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas
  72. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus
  73. Failure to Validate Association between 12p13 Variants and Ischemic Stroke
  74. Clonality Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of Colorectal Adenomas
  75. Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region
  76. Editorial: One Small Step for Metaplasia, but One Giant Leap for Biomarkers Is Needed
  77. Aspirin in the primary prevention of vascular disease
  78. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo
  79. Laparoscopic fundoplication compared with medical management for gastro-oesophageal reflux disease: cost effectiveness study
  80. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
  81. Biomarkers in Gastroenterology: Between Hope and Hype Comes Histopathology
  82. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus
  83. Clonality, Founder Mutations, and Field Cancerization in Human Ulcerative Colitis–Associated Neoplasia
  84. Analysis of the clonal architecture of the human small intestinal epithelium establishes a common stem cell for all lineages and reveals a mechanism for the fixation and spread of mutations
  85. Editorial: Dissecting GI Phenotype–Genotype Relationships in GERD and Dyspepsia: An SNP Here and an SNP There!
  86. Prevention of colorectal cancer by combining early detection and chemoprevention
  87. Optimizing Surveillance in Barrett's Esophagus: Response to Ruggeet al.
  88. Ectopic Expression of P-Cadherin Correlates with Promoter Hypomethylation Early in Colorectal Carcinogenesis and Enhanced Intestinal Crypt Fission In vivo
  89. Chemoprevention and Barrett's Esophagus: Decisions, Decisions
  90. Esophageal Adenocarcinoma in “Mice and Men”: Back to Basics!
  91. Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus
  92. Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Counterpoint
  93. Surgery versus radical endotherapies for early cancer and high grade dysplasia in Barrett's oesophagus
  94. Management of Barrett's Esophagus in the UK: Overtreated and Underbiopsied but Improved by the Introduction of a National Randomized Trial
  95. Gastrointestinal Oncology
  96. Mortality risks associated with Barrett’s oesophagus: authors' reply
  97. Faecal dimeric M2 pyruvate kinase in colorectal cancer and polyps correlates with tumour staging and surgical intervention
  98. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies
  99. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett's oesophagus
  100. Mechanisms of Field Cancerization in the Human Stomach: The Expansion and Spread of Mutated Gastric Stem Cells
  101. Genetics of Gastroesophageal Cancer: Paradigms, Paradoxes, and Prognostic Utility
  102. Chemoprevention of gastrointestinal cancer
  103. Mortality rates in patients with Barrett’s oesophagus
  104. Reply
  105. Die Montreal-Definition und -Klassifikation der gastroösophagealen Refluxkrankheit: Ein globales evidenzbasiertes Konsensus-Papier
  106. Chemoprevention of Colorectal Cancer
  107. Detection of Intestinal Metaplasia in Barrett's Esophagus
  108. A Phase II Study of Gefitinib Monotherapy in Advanced Esophageal Adenocarcinoma: Evidence of Gene Expression, Cellular, and Clinical Response
  109. Molecular changes in the progression of Barrett's oesophagus
  110. Adenocarcinoma in Barrett Esophagus
  111. Detection of Intestinal Metaplasia in Barrett's Esophagus: An Observational Comparator Study Suggests the Need for a Minimum of Eight Biopsies
  112. Hyperplastic polyps, serrated adenomas, and the serrated polyp neoplasia pathway
  113. Corrigendum to: The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4
  114. The effect of alginates on deoxycholic-acid-induced changes in oesophageal mucosal biology at pH 4
  115. The Evidence Base of Proton Pump Inhibitor Chemopreventative Agents in Barrett's Esophagus—The Good, The Bad, and The Flawed!
  116. Genetics of inflammatory bowel disease and associated cancers
  117. Met Receptor Signaling: A Key Effector in Esophageal Adenocarcinoma
  118. Drinking from the fountain of promise: biomarkers in the surveillance of Barrett's oesophagus--the glass is half full!
  119. Epidermal Growth Factor Receptor Kinase Domain Mutations in Esophageal and Pancreatic Adenocarcinomas
  120. Mechanisms of Disease: from stem cells to colorectal cancer
  121. Straight to test: introduction of a city-wide protocol driven investigation of suspected colorectal cancer
  122. Clonal Expansion in the Human Gut: Mitochondrial DNA Mutations Show Us the Way
  123. A methodologic analysis of chemoprevention and cancer prevention strategies for gastrointestinal cancer
  124. Mitochondrial DNA mutations are established in human colonic stem cells, and mutated clones expand by crypt fission
  125. Molecular biology of Barrett's cancer
  126. NSAID and oesophageal adenocarcinoma: randomised trials needed to correct for bias
  127. Cancer prevention
  128. Molecular pathways in bladder cancer: Part 2
  129. A family history of Barrett's oesophagus: Another risk factor?
  130. Review article: management of oesophageal adenocarcinoma - control of acid, bile and inflammation in intervention strategies for Barrett's oesophagus
  131. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop1 1Members of the workshop composed a group of international experts in BE from gastroenterology, surgery, pathology, molecular biology, outcomes, and epi...
  132. An Antiapoptotic Role for Gastrin and the Gastrin/CCK-2 Receptor in Barrett’s Esophagus
  133. Acid Suppression and Chemoprevention in Barrett’s Oesophagus
  134. Reply
  135. Reply
  136. The Role of β-Catenin Signaling in the Malignant Potential of Cystitis Glandularis
  137. Barrett?s Esophagus: Environmental Influences in the Progression of Dysplasia
  138. Clinical and molecular pathology of the metaplasia–dysplasia–carcinoma sequence in Barrett's oesophagus
  139. Commentary: The relation of obesity, reflux and its implications
  140. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor
  141. Gastro-Esophageal Reflux Disease and Bile Acids
  142. Curing oesophageal cancer
  143. 10-minute consultation: Gastro-oesophageal reflux disease
  144. Tumour necrosis factor-α in Barrett's oesophagus: a potential novel mechanism of action
  145. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon
  146. Contribution of cyclin d1 (CCND1) and E-cadherin (CDH1) polymorphisms to familial and sporadic colorectal cancer
  147. Esophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the west
  148. Down-regulation of E-cadherin and β-catenin in Helicobacter pylori Associated Gastritis and Gastric Carcinoma: An Immunohistochemical Study
  149. Transient P-cadherin expression in radiation proctitis; a model of mucosal injury and repair
  150. Effect of Ectopic Expression of Rat Trefoil Factor Family 3 (Intestinal Trefoil Factor) in the Jejunum of Transgenic Mice
  151. Differential T-cell responses in the pathogenesis of Barrett's metaplasia: A cephalo-caudal and surface to crypt gradient
  152. Inflammation promotes Barrettʼs metaplasia and cancer: a unique role for TNFα
  153. Barrett's metaplasia
  154. ABC of colorectal cancer: Molecular basis for risk factors
  155. Gastro-oesophageal cancer: death at the junction
  156. Aberrant P-cadherin expression is a feature of clonal expansion in the gastrointestinal tract associated with repair and neoplasia
  157. Barrett’s Esophagus: Disregulation of Cell Cycling and Intercellular Adhesion in the Metaplasia-Dysplasia-Carcinoma Sequence
  158. Barrett’s esophagus: an overview of the molecular biology *
  159. A colorectal cell line with alterations in E-cadherin and epithelial biology may be an in vitro model of colitis
  160. Cadherin adhesion in the intestinal crypt regulates morphogenesis, mitogenesis, motogenesis, and metaplasia formation
  161. Alterations in cadherin and catenin expression during the biological progression of melanocytic tumours
  162. Apoptotic and proliferative activity in the neoplastic progression of Barrett's oesophagus: a comparative study
  163. Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer
  164. Molecular Evolution of the Metaplasia-Dysplasia-Adenocarcinoma Sequence in the Esophagus
  165. Sequential changes in cadherin-catenin expression associated with the progression and heterogeneity of primary oesophageal squamous carcinoma
  166. Clonality of esophageal carcinomas: genetic and epigenetic events leading to loss of genomic stability
  167. Changes in Gene Structure and Regulation of E-Cadherin during Epithelial Development, Differentiation, and Disease
  168. Growth factors: potential for the management of solid epithelial tumours
  169. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables
  170. Expression of transforming growth factor alpha, epidermal growth factor receptor and epidermal growth factor in precursor lesions to gastric carcinoma
  171. Molecular surveillance of Barrett’s esophagus and putative strategies for genetic therapy
  172. Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett's metaplasia and the native oesophageal epithelium: Delineation of epithelial phenotype
  173. Maintenance of normal intestinal mucosa: function, structure, and adaptation.
  174. Gene expression in Barrett's mucosa: acute and chronic adaptive responses in the oesophagus.
  175. Screening for alimentary cancer
  176. The Administration of Supplementary Oxygen to Prevent Hypoxia During Upper Alimentary Endoscopy
  177. Development and growth of normal; metaplastic and dysplastic oesophageal mucosa
  178. Expression of Epidermal Growth Factor, Transforming Growth Factor Alpha and Their Receptor in Gastro-Oesophageal Diseases
  179. Epithelial stem cells in gastrointestinal morphogenesis, adaptation and carcinogenesis
  180. Glucose-6-phosphatase in normal adult human intestinal mucosa
  181. Epidermal growth factor in the oesophagus.
  182. Does hypothermia protect against the development of hepatitis in paracetamol overdose?
  183. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus.
  184. Behcet's syndrome in Scotland.
  185. Flow cytometry of oesophageal mucosal biopsies; epidermal growth factor receptor, and CD15
  186. Role of salivary epidermal growth factor in the pathogenesis of Barrett's columnar lined oesophagus
  187. Transforming growth factor alpha in epithelial proliferative diseases of the breast.
  188. Growth regulatory peptides in gastric mucosa
  189. Proliferating cell nuclear antigen in oesophageal diseases; correlation with transforming growth factor alpha expression.
  190. Epidermal growth factor receptors in the oesophagus.
  191. Flow-Cytometric Analysis of Growth-Regulatory Peptides and Their Receptors in Barrett's Oesophagus and Oesophageal Adenocarcinoma
  192. Abnormal expression of growth regulatory factors in Barrett's oesophagus
  193. Uptake of horseradish peroxidase by human oesophageal explants over 24 h
  194. Cardiorespiratory effects during gastrointestinal endoscopy
  195. Helicobacter pylori infection and gastric cancer.
  196. Evidence for hypomotility in non-ulcer dyspepsia: a prospective multifactorial study.
  197. Improved silver staining of nucleolar organiser regions in paraffin wax sections using an inverted incubation technique.
  198. Liver transplantation in patients with alcoholic cirrhosis.
  199. Changes in Keratan Sulphate Levels in the Serum of a Long Distance Runner
  200. Hypercalcaemia in rheumatoid arthritis revisited.